Population-based cohort study on comparative effectiveness and safety of biologics in inflammatory bowel disease

References

• D’HaensGRPanaccioneRHigginsPDThe London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn’s and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?Am J Gastroenterol20111062199212 quiz 21321045814
   PubMed Web of Science ®Google Scholar
• HazlewoodGSRezaieABormanMComparative effectiveness of immunosuppressants and biologics for inducing and maintaining remission in Crohn’s disease: a network meta-analysisGastroenterology20151482344354.e5 quiz e14–e1525448924
   PubMed Web of Science ®Google Scholar
• StidhamRWLeeTCHigginsPDSystematic review with network meta-analysis: the efficacy of anti-TNF agents for the treatment of Crohn’s diseaseAliment Pharmacol Ther201439121349136224749763
   PubMed Web of Science ®Google Scholar
• SinghSGargSKPardiDSWangZMuradMHLoftusEVJrComparative efficacy of biologic therapy in biologic-naive patients with Crohn disease: a systematic review and network meta-analysisMayo Clin Proc201489121621163525441399
   PubMed Web of Science ®Google Scholar
• DaneseSFiorinoGPeyrin-BirouletLBiological agents for moderately to severely active ulcerative colitis: a systematic review and network meta-analysisAnn Intern Med20141601070471124842416
   PubMed Web of Science ®Google Scholar
• StidhamRWLeeTCHigginsPDSystematic review with network meta-analysis: the efficacy of anti-tumour necrosis factor-alpha agents for the treatment of ulcerative colitisAliment Pharmacol Ther201439766067124506179
   PubMed Web of Science ®Google Scholar
• DaneseSVuittonLPeyrin-BirouletLBiologic agents for IBD: practical insightsNat Rev Gastroenterol Hepatol201512953754526284562
   PubMed Web of Science ®Google Scholar
• ZhangDXiongBLiXXuTYuMMeta-analysis: serious adverse events in Crohn’s disease patients treated with TNF-alpha inhibitorsHepatogastroenterology2013601261333134223340167
   PubMedGoogle Scholar
• SinghSNagpalSJMuradMHInflammatory bowel disease is associated with an increased risk of melanoma: a systematic review and meta-analysisClin Gastroenterol Hepatol201412221021823644389
   PubMed Web of Science ®Google Scholar
• FordACPeyrin-BirouletLOpportunistic infections with anti-tumor necrosis factor-alpha therapy in inflammatory bowel disease: meta-analysis of randomized controlled trialsAm J Gastroenterol201310881268127623649185
   PubMed Web of Science ®Google Scholar
• SiegelCAMardenSMPersingSMLarsonRJSandsBERisk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn’s disease: a meta-analysisClin Gastroenterol Hepatol20097887488119558997
   PubMed Web of Science ®Google Scholar
• WilliamsCJPeyrin-BirouletLFordACSystematic review with meta-analysis: malignancies with anti-tumour necrosis factor-alpha therapy in inflammatory bowel diseaseAliment Pharmacol Ther201439544745824444171
   PubMed Web of Science ®Google Scholar
• SinghSHeienHCSangaralinghamLRComparative effectiveness and safety of anti-tumor necrosis factor agents in biologic-naive patients with Crohn’s diseaseClin Gastroenterol Hepatol201614811201129.e627058635
   PubMed Web of Science ®Google Scholar
• GiesNKroekerKIWongKFedorakRNTreatment of ulcerative colitis with adalimumab or infliximab: long-term follow-up of a single-centre cohortAliment Pharmacol Ther201032452252820500733
   PubMed Web of Science ®Google Scholar
• SandbornWJSakurabaAWangAComparison of real-world outcomes of adalimumab and infliximab for patients with ulcerative colitis in the United StatesCurr Med Res Opin20163271233124126986449
   PubMed Web of Science ®Google Scholar
• LiuJSylwestrzakGRuggieriAPDeVriesAIntravenous versus subcutaneous anti-TNF-alpha agents for Crohn’s disease: a comparison of effectiveness and safetyJ Manag Care Spec Pharm201521755956626108380
   PubMed Web of Science ®Google Scholar
• AnanthakrishnanANCaganACaiTComparative effectiveness of Infliximab and Adalimumab in Crohn’s disease and ulcerative colitisInflamm Bowel Dis201622488088526933751
   PubMed Web of Science ®Google Scholar
• OstermanMTHaynesKDelzellEComparative effectiveness of infliximab and adalimumab for Crohn’s diseaseClin Gastroenterol Hepatol2014125811817.e323811254
   PubMed Web of Science ®Google Scholar
• Di DomenicantonioRCappaiGArcaMOccurrence of inflammatory bowel disease in central Italy: a study based on health information systemsDig Liver Dis201446977778224890621
   PubMedGoogle Scholar
• BenchimolEIGuttmannAMackDRValidation of international algorithms to identify adults with inflammatory bowel disease in health administrative data from Ontario, CanadaJ Clin Epidemiol201467888789624774473
   PubMed Web of Science ®Google Scholar
• WeitzenSLapaneKLToledanoAYHumeALMorVPrinciples for modeling propensity scores in medical research: a systematic literature reviewPharmacoepidemiol Drug Saf2004131284185315386709
   PubMed Web of Science ®Google Scholar
• SalleronJDaneseSD’AgayLPeyrin-BirouletLEffectiveness research in inflammatory bowel disease: a necessity and a methodological challengeJ Crohns Colitis20161091096110226944416
   PubMed Web of Science ®Google Scholar
• GisbertJPMarinACMcNichollAGChaparroMSystematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failedAliment Pharmacol Ther201541761362325652884
   PubMed Web of Science ®Google Scholar
• ParkSCJeenYTCurrent and emerging biologics for ulcerative colitisGut Liver201591182725547087
   PubMed Web of Science ®Google Scholar
• PetkauJMEksteenBSelective biologics for ulcerative colitis and Crohn’s disease – clinical utility of vedolizumabBiologics201610335227022240
   PubMedGoogle Scholar
• TargownikLETennakoonALeungSFactors associated with discontinuation of anti-TNF inhibitors among persons with IBD: a population-based analysisInflamm Bowel Dis201723340942028221250
   PubMed Web of Science ®Google Scholar